/SDZNY
SDZNY Stock - Sandoz Group AG
Healthcare|Drug Manufacturers - Specialty & GenericOTC
$72.97+0.16%
+$0.12 (+0.16%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.95
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $80.27
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SDZNY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$72.24 – $73.70
TARGET (TP)$83.92
STOP LOSS$67.13
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.26
52W High$74.87
52W Low$35.61
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.38B | $9.98B | $8.60B | $8.79B | $9.04B |
| Gross Profit | $4.93B | $4.56B | $4.05B | $4.15B | $4.16B |
| Gross Margin | 47.4% | 45.7% | 47.0% | 47.2% | 46.0% |
| Operating Income | $307.00M | $375.00M | $1.15B | $1.38B | $1.34B |
| Net Income | $1.00M | $77.00M | $784.05M | $830.15M | $433.64M |
| Net Margin | 0.0% | 0.8% | 9.1% | 9.4% | 4.8% |
| EPS | $0.00 | $0.18 | $1.82 | $1.93 | $1.01 |
Company Overview
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SDZNYBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$0.86
Q3 2025
EPS Surprise History
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 3, 2026 | — | — | — | — |
Q3 2025 | Aug 7, 2025 | — | $0.86 | — | — |
Q1 2025 | Mar 5, 2025 | — | — | — | — |
Q4 2024 | Oct 30, 2024 | — | — | — | — |
Q3 2024 | Aug 8, 2024 | — | — | — | — |
Latest News
Mirum Pharmaceuticals Files Patent Infringement Lawsuits To Block FDA Approval Of Generic Livmarli Following ANDA Filings By Sandoz, Annora, Zydus, Zenara
📉 NegativeBenzinga•Dec 19, 2025, 09:27 PM•Also:
Evotec Closed Its Previously Reported Sale Of The Just-evotec Biologics Toulouse Site Plus An Indefinite Technology License To Its Continuous Manufacturing Platform Technology To Sandoz, Potential Payments Of Over $650M Plus Royalties Of Up To 10 Biosimilar Molecules
📈 PositiveBenzinga•Dec 8, 2025, 10:51 AM•Also:
Mirum Pharmaceuticals Receives Paragraph IV Notice From Sandoz On Livmarli; Sandoz Alleges Five Livmarli Patents Invalid Or Unenforceable; To File Patent Infringement Suit Against Sandoz
📉 NegativeBenzinga•Nov 17, 2025, 09:57 PM•Also:
Evotec To Sell Evotec Biologics Toulouse Facility To Sandoz AG For ~$350M In Cash
📈 PositiveBenzinga•Nov 4, 2025, 09:35 PM•Also:
Frequently Asked Questions about SDZNY
What is SDZNY's current stock price?
Sandoz Group AG (SDZNY) is currently trading at $72.97 per share. The stock has moved +0.16% today.
What is the analyst price target for SDZNY?
No analyst price targets are currently available for this stock.
What sector is Sandoz Group AG in?
Sandoz Group AG operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.
What is SDZNY's market cap?
Sandoz Group AG has a market capitalization of $31.43 billion, making it a large-cap company.
Does SDZNY pay dividends?
No, Sandoz Group AG does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBAYRY
Bayer AG
$10.45
Mkt Cap: $41.1B
FSNUF
Fresenius SE & Co. KGaA
$55.90
Mkt Cap: $31.5B
HLNCF
Haleon plc
$4.93
Mkt Cap: $44.0B
JDHIF
JD Health International Inc.
$7.07
Mkt Cap: $22.6B
OTSKF
Otsuka Holdings Co., Ltd.
$58.42
Mkt Cap: $30.9B
OTSKY
Otsuka Holdings Co., Ltd.
$29.37
Mkt Cap: $32.0B
RYLPF
Koninklijke Philips N.V.
$25.93
Mkt Cap: $24.7B
SDMHF
Sartorius Stedim Biotech S.A.
$240.00
Mkt Cap: $23.3B
TEVJF
Teva Pharmaceutical Industries Limited
$28.61
Mkt Cap: $32.8B
TKPHF
Takeda Pharmaceutical Company Limited
$29.35
Mkt Cap: $46.4B
Explore stocks similar to SDZNY for comparison